QuidelOrtho Partners with Allo Hope Foundation to Enhance Prenatal Care for Maternal Alloimmunization

- QuidelOrtho partners with the Allo Hope Foundation to enhance prenatal care for families facing maternal alloimmunization.
- The collaboration aims to improve early testing, education, and access to care for underserved communities.
- QuidelOrtho seeks to empower families and transform prenatal care through better resources and informed support.
QuidelOrtho, a leader in diagnostic innovation (QDEL), announces a partnership with the Allo Hope Foundation to enhance prenatal care for families facing maternal alloimmunization. This collaboration aims to address maternal red blood cell alloimmunization, a condition that poses significant risks to fetal health and can lead to life-threatening hemolytic disease of the fetus and newborn (HDFN) if left undetected. By focusing on early testing, education, and strengthening the connections among healthcare providers, patients, and laboratory services, this initiative seeks to improve access to critical information and care, especially for underserved communities.
A Commitment to Maternal Health
The partnership responds to the urgent need for better resources and support for families dealing with alloimmunization. Many of these families often encounter difficulty in navigating the medical system and feel overwhelmed by their circumstances. QuidelOrtho's Executive Vice President of Global Portfolio Management and Marketing, Bryan Hanson, underscores the company's mission to advance diagnostics for a healthier future. He expresses that this collaboration with the Allo Hope Foundation is a manifestation of that commitment, ensuring that patients receive timely testing and necessary support throughout their pregnancy journey.
Improving Patient Experiences
Bethany Weathersby, the Founder and Executive Director of the Allo Hope Foundation, echoes this sentiment by emphasizing the importance of enhancing patient experiences. Families often feel isolated in their struggles, and through this partnership, the organizations aim to alleviate that sense of isolation by providing educational resources and fostering a supportive environment. Together, QuidelOrtho and the Allo Hope Foundation aspire to pave the way for better prenatal care, benefiting maternal and fetal health outcomes, particularly for those in historically underserved populations.
Transforming Prenatal Care
In conclusion, this collaboration represents a proactive approach to tackling the challenges associated with maternal alloimmunization. By utilizing their clinical expertise and trusted diagnostic capabilities, QuidelOrtho and the Allo Hope Foundation are working to empower families, raise awareness among healthcare providers, and transform prenatal care into a more equitable and informed experience for all involved.
Related Cashu News

Pulse Biosciences to Redeem Remaining Common Stock Warrants Following Share Price Conditions
Pulse Biosciences (Ticker: PLSE) implements a significant strategic decision as it moves to redeem the remaining common stock warrants from its rights offering dated July 3, 2024. This action comes in…

LivaNova PLC Board Changes Signal Strategic Shift and Enhanced Governance Amid Regulatory Challenges
LivaNova PLC (Ticker: LIVN) has made significant changes to its Board of Directors, which point to a strategic shift in its operational and risk management approaches. The company recently appointed J…

Penumbra's THUNDERBOLT Technology Receives FDA Clearance for Acute Ischemic Stroke Management
Penumbra, Inc. has achieved a significant milestone with the clearance of its innovative THUNDERBOLT™ technology by the U.S. Food and Drug Administration (FDA). This advancement plays a critical role…

Zimmer Biomet Drives Innovation in Orthopedics with Cementless Implants and Robotic Surgery Solutions
Zimmer Biomet Holdings is making strides in the orthopedic medical device industry, particularly with its innovative cementless implants and ROSA robotic-assisted surgery platform. These technological…